Publications by authors named "Agueda Prior-Espanol"
Fracture risk assessment in patients with chronic kidney disease (CKD) has been included in the CKD-MBD ("Chronic Kidney Disease-Mineral and Bone Disorders") complex in international and national nephrology guidelines, suggesting for the first time the assessment of bone mineral density (BMD) if the results can influence therapeutic decision-making. However, there is very little information on actual clinical practice in this population. The main objective of the ERCOS (ERC-Osteoporosis) study is to describe the profile of patients with CKD G3-5D with osteoporosis (OP) and/or fragility fractures treated in specialized nephrology, rheumatology and internal medicine clinics in Spain.
View Article and Find Full Text PDFChronic kidney disease (CKD) is a highly prevalent disease that has become a public health problem. Progression of CKD is associated with serious complications, including the CKD-mineral and bone disorder (CKD-MBD). Laboratory, bone and vascular abnormalities define this condition, and all have been independently related to cardiovascular disease and high mortality rates.
View Article and Find Full Text PDFArticle Synopsis
- The study evaluated the effectiveness and safety of biologic therapy (BT) in patients with neurobehçet's disease (NBD) who did not respond to glucocorticoids and conventional immunosuppressive drugs.
- Conducted as a national, multicenter, open-label study, it involved 41 patients and focused on clinical remission, glucocorticoid reduction, and lab parameter improvements as outcomes.
- Results showed that after six months, over half of the patients achieved complete remission, there was a significant reduction in prednisone dosage, and 90.2% maintained at least partial remission after an average follow-up of nearly 58 months, highlighting BT's effectiveness and moderate safety despite some adverse events.
The better understanding of the safety of biologic DMARDs (bDMARDs), as well as the emergence of new bDMARDs against different therapeutic targets and biosimilars have likely influenced the use patterns of these compounds over time. The aim of this study is to assess changes in demographic characteristics, disease activity and treatment patterns in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), or ankylosing spondylitis (AS) who started a first- or second-line biologic between 2007 and mid-2020. Patients diagnosed with RA, PsA or AS included in the BIOBADASER registry from January 2007 to July 2020 were included.
View Article and Find Full Text PDFArticle Synopsis
- The study analyzed the retention rates and predictors of response to biologic disease-modifying anti-rheumatic drugs (bDMARDs) and apremilast in patients with psoriatic arthritis (PsA) over an 18-year period.
- A total of 159 patients received various treatments, with a high discontinuation rate of 60%, primarily due to secondary failure (37%).
- Key predictors for lack of response included male sex, number of swollen joints, and depression, with the best retention observed for anti-TNF agents like infliximab and etanercept.
Imbalance Between Omega-6- and Omega-3-Derived Bioactive Lipids in Arthritis in Older Adults.
J Gerontol A Biol Sci Med Sci
February 2021
Elderly-onset rheumatoid arthritis (EORA) and polymyalgia rheumatica (PMR) are common rheumatic diseases in older adults. Oxylipins are bioactive lipids derived from omega-6 (n-6) and omega-3 (n-3) polyunsaturated fatty acids (PUFAs) that serve as activators or suppressors of systemic inflammation. We hypothesized that arthritis symptoms in older adults were related to oxylipin-related perturbations.
View Article and Find Full Text PDFObjective: Septic arthritis is a medical emergency and crystal-induced arthritis is a risk factor for its development. If both occur simultaneously, crystal-induced arthritis may mask the diagnosis of infection and delay antibiotic therapy.
Method: Retrospective analysis of patients with coexistence of septic and crystal-induced arthritis.